Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Therapeutics, and Enlaza also raising nine-figure sums.
Zenas said its Series C will keep the company ticking over as it works towards a series of readouts in clinical trials of its bifunctional monoclonal antibody obexelimab in autoimmune diseases.
